Why we should stop performing vertebroplasties for osteoporotic spinal fractures

Rachelle Buchbinder, Lucy Busija

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)


While vertebroplasty enjoys continued use in some settings, there is now high-moderate quality evidence based on systematic review that includes five placebo-controlled trials that it provides no benefits over placebo and these results do not differ according to pain duration (≤6 vs >6 weeks). A clinically important increased risk of incident symptomatic vertebral fractures or other serious adverse events cannot be excluded due to small event numbers. Serious harms including cord compression, ventricular perforation, pulmonary embolism, infection and death have been reported. This unfavourable risk-benefit ratio should be convincing doctors and patients to stop the use of vertebroplasty. At the very least, clinicians should fully inform their patients about the evidence including the likelihood of improving without vertebroplasty and the potential harms, so that patients can make evidence-informed decisions about their treatment. They should also warn patients about the pitfalls of relying on information sourced from the internet or from 'awareness raising' campaigns.

Original languageEnglish
Pages (from-to)1367-1371
Number of pages5
JournalInternal Medicine Journal
Issue number11
Publication statusPublished - 1 Nov 2019


  • disinvestment
  • evidence-based practice
  • vertebroplasty

Cite this